1. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer;Bogani;Int. J. Gynecol. Cancer,2024
2. Drug-induced and iatrogenic infiltrative lung disease;Camus;Clin. Chest Med.,2004
3. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment;Conte;ESMO Open.,2022
4. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer;Cristea;Gynecol. Oncol.,2024
5. Elahere. Prescribing Information (Package Insert). ImmunoGen Inc. Published online March 1, 2024. Accessed June 1, 2024. https://elahere.com/pdf/prescribing-information.pdf.